Streetbeat News

Revenues

ATRA

Atara Biotherapeutics has received FDA acceptance and priority review for its Biologics License Application for Tabelecleucel, a treatment for Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease. The Prescription Drug User Fee Act (PDUFA) target action date is January 15, 2025. If approved, Tabelecleucel would be the first approved therapy in the U.S. for this condition. The acceptance triggers a $20 million milestone payment from Pierre Fabre Laboratories, with an additional $60 million milestone if approved by the FDA.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2024 | 1:05 pm

JNJ

Johnson & Johnson (J&J) anticipates lower sales growth for its innovative medicines in the second half of 2024 due to the entry of Stelara biosimilars in Europe. Additionally, J&J does not expect any future sales from its COVID-19 vaccine despite Q2 sales.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2024 | 1:05 pm

AMZN

Numerator has released early data for Prime Day 2024, revealing an average spend per order of $60.03 and that 50% of households placed two or more orders.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2024 | 1:04 pm

FCCO

First Community (NASDAQ:FCCO) reported Q2 earnings of $0.42 per share, beating the $0.36 estimate. Sales were $16.33M, surpassing the $15.52M estimate. Despite a slight decrease in EPS from last year, sales increased by 7.52%.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2024 | 1:03 pm

UAVS

AgEagle Aerial Systems (UAVS) has announced the sale of 10 eBee X lightweight mapping drones to Brazil's National Department of Transport Infrastructure. These drones will be used for public safety and highway monitoring. The financial terms of the deal were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2024 | 1:02 pm

COHR

Coherent (NYSE:COHR) has received diverse analyst ratings over the past three months, with a mix of bullish and neutral perspectives. Analysts have set a 12-month average price target of $73.4, reflecting a 10.54% increase from the previous target. Key analysts have maintained or raised their ratings, with price targets ranging from $65 to $90. Despite revenue challenges, Coherent's financial metrics such as net margin, ROE, and ROA surpass industry averages, although its debt-to-equity ratio is higher than the industry norm.

Portfolio Pulse from Benzinga Insights

July 17, 2024 | 1:01 pm

CSLR

Complete Solar has raised $10 million from a Chinese energy company, which could provide a significant boost to its operations and market presence.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2024 | 12:54 pm

NBR

Nabors Industries has announced its preliminary Q2 2024 operating results, reporting revenue of approximately $735 million, adjusted EBITDA of $218 million, and adjusted free cash flow between $55 million and $60 million. The company highlighted international expansion and stable U.S. activity, with an average of 68.7 rigs in the Lower 48 and 84.4 rigs internationally. Full results will be released on July 23, 2024, followed by an earnings call on July 24, 2024.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2024 | 12:53 pm

SYF

Synchrony Financial reported a 7% year-over-year increase in Q2 net interest income, reaching $4.41 billion.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2024 | 12:50 pm

SYF

Synchrony Financial's Q2 report shows a mixed performance with a 1% decrease in purchase volume, an 8% increase in loan receivables, and a 48 basis points drop in net interest margin to 14.46%. Other key metrics include a 2% increase in average active accounts and a 14% decrease in new accounts.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2024 | 12:49 pm